Literature DB >> 24939702

MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1.

Jing Dong1, Long Sui1, Qing Wang1, Mingjun Chen1, Hong Sun1.   

Abstract

The downregulation of microRNA‑26a (miR‑26a) has been reported in numerous types of cancer, but its detailed functional role in cervical cancer is not yet clear. In the present study, the expression of miR‑26a in human cervical cancer was confirmed and its contribution to cervical cancer progression was investigated. The expression of miR‑26a was determined by reverse transcription quantitative polymerase chain reaction in human cervical tissues and cell lines. Cell growth and invasion were detected by cell counting kit‑8, colony‑forming assays and transwell assays following restoration of miR‑26a expression. Protein tyrosine phosphatase type IVA 1 (PRL‑1) was further validated as a target of miR‑26a by a functional luciferase assay and western blot analysis. In addition, the overexpression of miR‑26a in tumor formation in SCID mice was investigated in vivo, and the association between miR‑26a and PRL‑1 was assayed by Pearson's correlation coefficient. First, it was identified that miR‑26a was significantly downregulated in cervical cancer compared with the paired adjacent tissues. Forced expression of miR‑26a suppressed cell proliferation and invasion in vitro and inhibited the growth of tumor xenografts in vivo. PRL‑1 was determined as a novel target for miR‑26a and knockdown of PRL‑1 partially phenocopied the effect of miR‑26a restoration. In addition, PRL‑1 expression was inversely correlated with miR‑26a expression in cervical cancer tissues. In conclusion, the results demonstrated the role of miR‑26a in cervical cancer pathogenesis and suggest it may be used as a potential novel therapeutic strategy for cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24939702     DOI: 10.3892/mmr.2014.2335

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  20 in total

1.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

Review 2.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

3.  Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.

Authors:  Min Luo; Dongxiang Shen; Wei Wang; Jiang Xian
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.

Authors:  Tandrima Mitra; Selvakumar Elangovan
Journal:  Mol Cell Biochem       Date:  2021-08-28       Impact factor: 3.396

Review 5.  The role of microRNA-26a in human cancer progression and clinical application.

Authors:  Jing Chen; Kai Zhang; Yuejuan Xu; Yanping Gao; Chen Li; Rui Wang; Longbang Chen
Journal:  Tumour Biol       Date:  2016-04-02

6.  Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.

Authors:  Mengyue Chen; Yugang Chi; Hongwei Chen; Limei Zhao
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

7.  Differential MicroRNA Expression in Human Macrophages with Mycobacterium tuberculosis Infection of Beijing/W and Non-Beijing/W Strain Types.

Authors:  Lin Zheng; Eric Leung; Nelson Lee; Grace Lui; Ka-Fai To; Raphael C Y Chan; Margaret Ip
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

8.  MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma.

Authors:  Torsten Voigtländer; Shashi K Gupta; Sabrina Thum; Jasmin Fendrich; Michael P Manns; Tim O Lankisch; Thomas Thum
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls.

Authors:  Xinjing Wang; Xiongxiong Lu; Yuan Fang; Hao Chen; Xiaxing Deng; Chenghong Peng; Hongwei Li; Baiyong Shen
Journal:  Med Sci Monit       Date:  2014-10-19

10.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.